<DOC>
	<DOCNO>NCT00276666</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , lomustine , vincristine , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together combination chemotherapy surgery may kill tumor cell remain . PURPOSE : This phase II trial study give radiation therapy together combination chemotherapy see well work treat young patient metastatic medulloblastoma undergone surgery .</brief_summary>
	<brief_title>Radiation Therapy Combination Chemotherapy Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity hyperfractionated accelerated radiotherapy ( HART ) young patient metastatic medulloblastoma . - Determine toxicity chemotherapy ( vincristine radiotherapy 8 course lomustine , cisplatin , vincristine radiotherapy ) association HART patient . OUTLINE : This multicenter study . - Radiotherapy vincristine : Beginning 4-6 week surgery , patient undergo hyperfractionated accelerated radiotherapy ( HART ) twice day , 5 day week , 5 week . Patients also receive vincristine IV weekly 8 week begin week 1* . Approximately 6-8 week completion radiotherapy , patient proceed maintenance chemotherapy . NOTE : *The first 7 patient undergo radiotherapy without receive vincristine - Maintenance chemotherapy : Patients receive oral lomustine day 1 cisplatin IV 6 hour day 1 vincristine IV day 1 , 8 , 15 . Treatment repeat every 6 week 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 29 patient accrue study .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven medulloblastoma The following variant medulloblastoma also eligible : Nodular/desmoplastic medulloblastoma Medullomyoblastoma Melanotic medulloblastoma Metastatic disease , meet least 1 follow criterion : Unequivocal evidence pre postoperative MR scan supratentorial ( stage M2 ) metastases and/or spinal metastasis ( stage M3 ) Tumor cell see cytospin analysis lumbar cerebral spinal fluid ( CSF ) ( stage M1 ) perform 15 day 21 day surgery Involvement CSF pathways tumor define unequivocal identification primitive neuroectodermal cell , either cytological ground combination cytological immunocytological feature ( e.g. , reactivity GFAP neuronal marker , synaptophysin ) Underwent surgery remove tumor 6 week ago PATIENT CHARACTERISTICS : Hemoglobin ≥ 10 g/dL Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Neurologically stable ( improve ) week start radiotherapy Lansky ( 116 year ) Karnofsky ( &gt; 16 year ) performance status 30100 % No active infection No prior malignant disease Not pregnant nursing No syndrome recognize potential increased sensitivity radiotherapy and/or chromosomal fragility Not require anesthesia No hearing loss renal impairment would make patient unable comply 'Packer ' chemotherapy protocol PRIOR CONCURRENT THERAPY : No steroid , possible , start radiotherapy OR stable reduce dose steroid week start radiotherapy No prior chemotherapy radiotherapy Dexamethasone use antiemetic unless therapy fail</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>untreated childhood medulloblastoma</keyword>
</DOC>